NY-ESO-1 is a tumor-specific antigen of the cancer/testis antigen family and is encoded by a gene located at Xq28. It is composed of 180 amino acids with a molecular weight of 18 kD. NY-ESO-1 is strongly expressed in various types of cancers, but not in normal somatic tissues or cells except normal testes, ovary, and placenta.
NY-ESO-1 was first identified as a tumor antigen in 1997 by Chen et al. (1997a) using sera from a patient with esophageal squamous cell carcinoma after serological analysis of recombinant cDNA expression libraries (SEREX). Shortly afterwards, Jäger et al. (1998) and Wang et al. (1998a) independently reported that NY-ESO-1 could be recognized by T cells from melanoma patients. Thus, NY-ESO-1 can induce both antibody and T-cell responses in the...
KeywordsEsophageal Squamous Cell Carcinoma Synovial Cell Sarcoma Strong Immunogenicity Antigen Family Beneficial Clinical Outcome
We would like to thank Drs. Adebusola Alagbala Ajibade and Christopher Loo for manuscript editing.
- Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337CrossRefPubMedGoogle Scholar
- Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265–270CrossRefPubMedPubMedCentralGoogle Scholar
- Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A (2000) Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 191:625–630CrossRefPubMedPubMedCentralGoogle Scholar
- Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917–924CrossRefPubMedPubMedCentralGoogle Scholar
- Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD (2011) CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother: CII 60:1137–1146CrossRefPubMedPubMedCentralGoogle Scholar